Dynamic Substrate Mapping (DSM) for Ischemic VT (DSM)

February 1, 2019 updated by: Abbott Medical Devices

Clinical Feasibility of Using Dynamic Substrate Mapping to Guide Ablation of Ischemic Ventricular Tachycardia

This is a prospective, non-randomized study to determine the feasibility of using a new technique called Dynamic Substrate Mapping (DSM) to help guide the treatment of ischemic ventricular tachycardia (IVT). We hypothesize that DSM will lead to simpler, more effective ablation of IVT. Results from this study will be used to determine if further clinical investigation is warranted.

Study Overview

Study Type

Interventional

Enrollment (Actual)

5

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States
        • Northwestern University
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States
        • Hospital at the University of Pennsylvania
    • Virginia
      • Norfolk, Virginia, United States
        • Sentara Norfolk General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Have an ICD or CRT-D device
  • Had at least 3 documented device therapies to treat VT over last 3 months
  • Clinical VT is confirmed or suspected to be of ischemic origin
  • Scheduled for VT ablation procedure
  • LVEF > or = 20%

Exclusion Criteria:

  • Inadequate AAD washout (amiodarone should be maintained at current dose)
  • Unstable angina
  • Active ischemia
  • Cardiac surgery within prior 2 months
  • Evidence of infection
  • Prosthetic mitral or aortic valve or mitral/aortic valvular heart disease requiring surgical intervention
  • History of embolic event
  • Myocardial infarction within prior 6 weeks
  • Enrolled in another study
  • Recurrent sepsis or otherwise not a candidate for catheterization
  • Hypercoagulable state or inability to tolerate heparin therapy during procedure
  • Has had an atriotomy or ventriculotomy within prior 4 months
  • Life expectancy < 6 months
  • Class IV NYHA classification

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: DSM
Treatment using DSM to guide ablation
Radiofrequency ablation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of serious adverse events (SAEs)
Time Frame: 30 days
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David Callans, MD, University of Pennsylvania
  • Principal Investigator: Jason Jacobson, MD, Northwestern University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2007

Primary Completion (Actual)

April 1, 2009

Study Completion (Actual)

April 1, 2009

Study Registration Dates

First Submitted

November 14, 2007

First Submitted That Met QC Criteria

November 14, 2007

First Posted (Estimate)

November 15, 2007

Study Record Updates

Last Update Posted (Actual)

February 4, 2019

Last Update Submitted That Met QC Criteria

February 1, 2019

Last Verified

February 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe